Being an antibody development company that has ventured and prevailed into the CAR-T development space, ProMab holds several advantages over our competitors for bispecific antibody development.
First and foremost, our antibody development platform is well established:
- Over 2000+ Monoclonal Antibody Hybridoma Cell Lines
- Humanized Mouse Model
- Human Antibody Library
- Alpaca / Llama Antibody Library
- Many more exploratory options.
Another unique advantage ProMab offers is that we have developed many different stable cell lines with tumor antigens to validate many bispecific antibodies. For example: Hela-CD19 cells, CHO-CD22, CHO-CS1, CHO-BCMA, CHO-CD37 (link), and other).
Additionally, ProMab can also offer our extensive list of CAR-T constructs. Our CAR-T cells can then be used alongside in validating the bispecific antibodies to compare and contrast the efficacy of the study.
ProMab has also invested in cutting-edge technology with in-vitro assays utilizing XCelligenceTM System (ACEA/Agilent), as well as an in-house animal facility for in-vivo validation.
Furthermore, ProMab has access to large scale GMP production on-site via our partners: GMP Manufacturing at JOINN Park. With over 100,000 sqft of lab space, we have a large capacity for up to 1000L bioreactors with large support areas for GMP manufacturing.
ProMab Case Study: Bispecific Antibodies
- Ulrich Brinkmann a and Roland E. Kontermann. The making of bispecific antibodies, MABS, 2017, VOL. 9, NO. 2, 182–212